NASDAQ · TVRD
Tvardi Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TVRD: Nov 12, 2026
Tvardi Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.51. The reported EPS for the same quarter last year was $-0.59.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.51 | $-0.28 | $-0.74 | 4 |
| Dec 2026 | $-0.55 | $-0.29 | $-0.85 | 4 |
| Mar 2027 | $-0.60 | $-0.37 | $-0.82 | 2 |
| Jun 2027 | $-0.64 | $-0.47 | $-0.82 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews · Barchart- Fintel · Sep 15, 4:56 AM EDTTvardi Therapeutics Consensus Price Target Increased by 11.76% to $9.69The average one-year price target for Tvardi Therapeutics (NASDAQCM:TVRD) has been revised to $9.69 / share. This is an increase of 11.76% from the prior estimate of $8.67 dated August 25, 2026. These figures represent aggregate analyst targets and do not constitute a recommenda
- Zacks · Jul 9, 10:52 AM EDTTVRD Stock Rallies 149% So Far This Week: Here's What You Should KnowTvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
- RTTNews · Jul 7, 8:52 AM EDTTvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study(RTTNews) – Tvardi Therapeutics, Inc. (TVRD) has reported results from its Phase 1 study of TTI-109, its next-generation STAT3 inhibitor, confirming the drug's prodrug design and improved tolerability compared to its predecessor TTI-101.
- RTTNews · Jun 29, 10:58 PM EDTTop Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?(RTTNews) – Today's top gainers include Universe Pharma, which expanded its pharmaceutical patent portfolio; Decoy Therapeutics, following the announcement of a PIPE financing; QuidelOrtho, on reports that it is exploring the sale of one of its business units; and SELLAS, which i
- RTTNews · Apr 1, 7:26 AM EDTTvardi Therapeutics Narrows FY25 Loss, Prepares For Key STAT3 Clinical Readouts In 2026(RTTNews) – Tvardi Therapeutics, Inc. (TVRD) reported fourth-quarter and full-year 2025 financial results and highlighted progress across its STAT3-targeted pipeline, including upcoming data readouts for both its next-generation inhibitor TTI-109 and its lead candidate TTI-101.
- Zacks · Nov 18, 9:55 AM ESTTvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowTvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Zacks · Oct 28, 9:55 AM EDTHere's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock NowTvardi (TVRD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround
- Zacks · Oct 16, 9:35 AM EDTDown 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a TurnaroundThe heavy selling pressure might have exhausted for Tvardi (TVRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Barchart · Oct 14, 2:50 PM EDTStocks Settle Sharply Higher on Trade Hopes and AI OptimismThe S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.56%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.18%. December E-mini S&P futures (ESZ25 ) rose +1.47%, and December E-mini Nasdaq futures…
- Zacks · Oct 14, 11:24 AM EDTTVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key GoalsTvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
- Barchart · Oct 13, 7:39 PM EDTStocks Supported by Trade Hopes and Broadcom’s AI DealThe S&P 500 Index ($SPX ) (SPY ) today is up +1.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.97%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.52%. December E-mini S&P futures (ESZ25 ) are up +1.12%, and December E-mini Nasdaq futures…
- Barchart · Oct 13, 7:39 PM EDTStocks Rebound as President Trump Softens China RhetoricThe S&P 500 Index ($SPX ) (SPY ) today is up +1.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.91%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.67%. December E-mini S&P futures (ESZ25 ) are up +1.22%, and December E-mini Nasdaq futures…
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Tvardi Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.